



Maintenance Therapy for Small Cell Lung Cancer: What Patients Should Know Show Notes

This episode explores maintenance therapy—often referred to by experts today as continuation therapy—and its role in the treatment of extensive-stage small cell lung cancer (ES-SCLC). Through a thoughtful conversation between thoracic oncologist Dr. Martin Edelman and patient host Jill Feldman, we discuss why small cell lung cancer frequently returns after initial treatment, how immunotherapy is helping some patients achieve longer-lasting responses, and the questions patients should ask their care team about treatment options, clinical trials, and quality of life.

Guests:

Dr. Martin Edelman

Dr. Martin Edelman is Chair of Hematology-Oncology at Fox Chase Cancer Center and a nationally recognized thoracic oncologist. Throughout his distinguished career, he has helped advance lung cancer treatment through clinical research, immunotherapy development, and patient-centered care. His work has contributed to improving outcomes for patients with both small cell and non-small cell lung cancer.

Jill Feldman

Jill Feldman is a lung cancer survivor, patient advocate, and nationally recognized voice in the lung cancer community. Through her advocacy work, Jill helps patients and families navigate diagnosis, treatment decisions, survivorship, and the emotional realities of living with lung cancer.

Episode Highlights:

- **Why Small Cell Lung Cancer Returns:** Dr. Edelman explains why small cell lung cancer is one of the most genetically complex cancers, making it particularly challenging to treat and more likely to recur after an initial response.



- The Role of Immunotherapy: How immunotherapy has changed the treatment landscape for extensive-stage small cell lung cancer and why some patients are experiencing longer-lasting responses than ever before.
 - Can Doctors Predict Who Will Benefit Most? A discussion about current limitations in identifying which patients are most likely to experience durable responses and what researchers are working to uncover.
 - Clinical Trials from Day One: Why patients should ask about clinical trials early in their treatment journey and how research is driving the next generation of therapies for small cell lung cancer.
 - Quality of Life Matters: The importance of supportive care, symptom management, patient education, and balancing treatment goals with everyday life.
-

Resources

- [LCFA's First 7 Days](#): A Roadmap for the Newly Diagnosed
 - [Learn more about Small Cell Lung Cancer](#)
 - [Find a Clinical Trial](#)
-

LCFA's mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.

While raising funds to support lung cancer research, LCFA will raise the public's awareness and serve as a resource for patients or anyone seeking answers, hope, and access to updated treatment information, scientific investigation, and clinical trials.

You can also join the conversation with LCFA on [Facebook](#), [Twitter](#), and [Instagram](#).